258 related articles for article (PubMed ID: 29040988)
21. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
22. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus.
Kuo YH; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
Kaohsiung J Med Sci; 2022 Mar; 38(3):268-276. PubMed ID: 34687140
[TBL] [Abstract][Full Text] [Related]
23. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
24. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.
Yoh K; Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Aizawa N; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S
Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057827
[TBL] [Abstract][Full Text] [Related]
25. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
26. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
[TBL] [Abstract][Full Text] [Related]
27. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
28. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection.
Nakajima T; Karino Y; Hige S; Suii H; Tatsumi R; Yamaguchi M; Arakawa T; Kuwata Y; Toyota J
Ann Hepatol; 2022; 27(1):100566. PubMed ID: 34688887
[TBL] [Abstract][Full Text] [Related]
29. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.
Li M; Li Y; Zhang Y; Wang X; Lin C
Medicine (Baltimore); 2024 Feb; 103(7):e37212. PubMed ID: 38363923
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
31. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
Lin CP; Liang PC; Huang CI; Yeh ML; Hsu PY; Hsu CT; Wei YJ; Liu TW; Hsieh MY; Hou NJ; Jang TY; Lin YH; Wang CW; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
PLoS One; 2021; 16(2):e0245479. PubMed ID: 33539408
[TBL] [Abstract][Full Text] [Related]
32. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
Yamazaki T; Joshita S; Umemura T; Usami Y; Sugiura A; Fujimori N; Kimura T; Matsumoto A; Igarashi K; Ota M; Tanaka E
PLoS One; 2018; 13(4):e0195632. PubMed ID: 29617443
[TBL] [Abstract][Full Text] [Related]
33. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
34. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.
Mücke VT; Thomas D; Mücke MM; Waidmann O; Zeuzem S; Sarrazin C; Pfeilschifter J; Vermehren J; Finkelmeier F; Grammatikos G
Liver Int; 2019 Nov; 39(11):2174-2183. PubMed ID: 31207039
[TBL] [Abstract][Full Text] [Related]
35. Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in Egypt.
Badawi R; Alboraie M; Abd-Elsalam S; Abourahma MZ; Ramadan HK; Ahmed OA; Fouad MHA; Soliman S; Mohareb DA; Haydara T; Alnabawy SM; El Kassas M
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):1005-1011. PubMed ID: 30727931
[TBL] [Abstract][Full Text] [Related]
36. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
37. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
Backus LI; Belperio PS; Shahoumian TA; Mole LA
Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
[TBL] [Abstract][Full Text] [Related]
38. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
[TBL] [Abstract][Full Text] [Related]
39. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.
Lleo A; Aglitti A; Aghemo A; Maisonneuve P; Bruno S; Persico M;
Dig Liver Dis; 2019 Feb; 51(2):310-317. PubMed ID: 30473220
[TBL] [Abstract][Full Text] [Related]
40. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Tamaki N; Kurosaki M; Yasui Y; Mori N; Tsuji K; Hasebe C; Joko K; Akahane T; Furuta K; Kobashi H; Kimura H; Yagisawa H; Marusawa H; Kondo M; Kojima Y; Yoshida H; Uchida Y; Loomba R; Izumi N
Clin Infect Dis; 2021 Nov; 73(9):e3349-e3354. PubMed ID: 33544129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]